ONCAlert | Upfront Therapy for mRCC

Lung Cancer VIEW MORE >>

The lack of approved therapies to target EGFR exon 20 insertion mutations, the third most common form of EGFR mutations, led to the study of osimertinib in combination with cetuximab in patients with advanced EGFR-mutant non–small cell lung cancer.
 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.